Verve Therapeutics, Inc. (VERV)
NASDAQ: VERV · Real-Time Price · USD
4.740
-0.480 (-9.20%)
Mar 31, 2025, 1:19 PM EDT - Market open
Verve Therapeutics Stock Forecast
VERV's stock price has decreased by -63.78% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Verve Therapeutics stock have an average target of 25.5, with a low estimate of 15 and a high estimate of 40. The average target predicts an increase of 437.97% from the current stock price of 4.74.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Verve Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 4 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Mar 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +216.46% | Mar 25, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $17 → $15 | Buy | Maintains | $17 → $15 | +216.46% | Mar 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $14 → $15 | Strong Buy | Maintains | $14 → $15 | +216.46% | Feb 28, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $29 → $32 | Strong Buy | Maintains | $29 → $32 | +575.11% | Nov 6, 2024 |
Financial Forecast
Revenue This Year
17.30M
from 32.33M
Decreased by -46.49%
Revenue Next Year
11.99M
from 17.30M
Decreased by -30.69%
EPS This Year
-2.96
from -2.35
EPS Next Year
-3.00
from -2.96
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 33.6M | 25.8M | 47.3M | ||
| Avg | 17.3M | 12.0M | 20.5M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.9% | 49.3% | 294.0% | ||
| Avg | -46.5% | -30.7% | 70.8% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.39 | -2.31 | -2.18 | ||
| Avg | -2.96 | -3.00 | -2.87 | ||
| Low | -3.54 | -3.70 | -3.50 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.